NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer

A novel mTORC1/2 inhibitor (MTI-31) inhibits tumor growth, epithelial-mesenchymal transition, metastases and improves cancer immunity in preclinical lung cancer models

(2019) Qianwen Zhang et al.   CLINICAL CANCER RESEARCH

PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer

(2019) Constantia Pantelidou et al.   Cancer Discovery

When the good go bad: Mutant NPM1 in acute myeloid leukemia

(2018) Preethi Kunchala et al.   BLOOD REVIEWS

Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here

(2018) Maryann J. Kwa et al.   CANCER

Programmed death 1 Ligand 1 expression in breast cancer and its association with patients' clinical parameters

(2018) Zhandong Wang et al.   Journal of Cancer Research and Therapeutics

Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells

(2017) Xun Wang et al.   IMMUNOLOGY LETTERS

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

(2017) Marian L. Burr et al.   NATURE

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

(2017) Enfu Hui et al.   SCIENCE

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

Nucleophosmin: from structure and function to disease development

(2016) Joseph K. Box et al.   BMC MOLECULAR BIOLOGY

PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma

(2016) Melanie Ruf et al.   INTERNATIONAL JOURNAL OF CANCER

High expression of B23 is associated with tumorigenesis and poor prognosis in bladder urothelial carcinoma

(2016) Haiping Wang et al.   Molecular Medicine Reports

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

(2016) Chia-Wei Li et al.   Nature Communications

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes

(2016) Sasha E. Stanton et al.   JAMA Oncology

Clinical significance of tumor-infiltrating lymphocytes in breast cancer

(2016) Sasha E. Stanton et al.   Journal for ImmunoTherapy of Cancer

PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes

(2015) H. R. Ali et al.   ANNALS OF ONCOLOGY

Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN  That Induce PD-L1 Expression in Head and Neck Cancer

(2015) F. Concha-Benavente et al.   CANCER RESEARCH

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade

(2015) D. M. Woods et al.   Cancer Immunology Research

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

(2014) S. Loi et al.   ANNALS OF ONCOLOGY

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors

(2014) J. Balmaña et al.   ANNALS OF ONCOLOGY

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

(2014) S. Muenst et al.   BREAST CANCER RESEARCH AND TREATMENT

Targeting Nucleophosmin 1 Represents a Rational Strategy for Radiation Sensitization

(2014) Konjeti R. Sekhar et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

PD-L1 Expression in Triple-Negative Breast Cancer

(2014) E. A. Mittendorf et al.   Cancer Immunology Research

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

(2013) Sherene Loi et al.   JOURNAL OF CLINICAL ONCOLOGY

Triple-negative breast cancer: epidemiological considerations and recommendations

(2012) P. Boyle   ANNALS OF ONCOLOGY

Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

(2012) M. R. Green et al.   CLINICAL CANCER RESEARCH

Nucleophosmin is essential for c-Myc nucleolar localization and c-Myc-mediated rDNA transcription

(2012) Z Li et al.   ONCOGENE

Nucleophosmin is overexpressed in thyroid tumors

(2010) Annalisa Pianta et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Nucleophosmin C-terminal Leukemia-associated Domain Interacts with G-rich Quadruplex Forming DNA

(2010) Luca Federici et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PD-1-Mediated Suppression of IL-2 Production Induces CD8+ T Cell Anergy In Vivo

(2009) S. Chikuma et al.   JOURNAL OF IMMUNOLOGY

Acetylated NPM1 Localizes in the Nucleoplasm and Regulates Transcriptional Activation of Genes Implicated in Oral Cancer Manifestation

(2009) J. Shandilya et al.   MOLECULAR AND CELLULAR BIOLOGY

The nucleolar SUMO-specific protease SENP3 reverses SUMO modification of nucleophosmin and is required for rRNA processing

(2008) Markus Haindl et al.   EMBO REPORTS

NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells

(2008) W Qi et al.   ONCOGENE

Nucleophosmin interacts directly with c-Myc and controls c-Myc-induced hyperproliferation and transformation

(2008) Z. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA